PT87190B - Processo para a preparacao de composicoes farmaceuticas para a reducao dos efeitos indesejaveis das beta-lactaminas - Google Patents

Processo para a preparacao de composicoes farmaceuticas para a reducao dos efeitos indesejaveis das beta-lactaminas Download PDF

Info

Publication number: PT87190B
Authority: PT; Portugal
Prior art keywords: bacteria; strains; lactamases; produce; process according
Prior art date: 1987-04-10

Application number

PT87190A

Other languages

English (en)

Portuguese (pt)

Other versions

PT87190A (pt

Inventor

Cyrille Tancrede

Antoine Andremont

Roger Labia

Florence Leonard

Original Assignee

Roussy Inst Gustave

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-04-10

Filing date

1988-04-08

Publication date

1992-08-31

1988-04-08 Application filed by Roussy Inst Gustave filed Critical Roussy Inst Gustave

1988-05-01 Publication of PT87190A publication Critical patent/PT87190A/pt

1992-08-31 Publication of PT87190B publication Critical patent/PT87190B/pt

Links

230000000694 effects Effects 0.000 title claims abstract description 21
238000000034 method Methods 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 5
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
102000006635 beta-lactamase Human genes 0.000 claims abstract description 12
108020004256 Beta-lactamase Proteins 0.000 claims abstract description 6
241000894006 Bacteria Species 0.000 claims description 16
241000282414 Homo sapiens Species 0.000 claims description 14
230000001580 bacterial effect Effects 0.000 claims description 8
241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
108090000204 Dipeptidase 1 Proteins 0.000 claims description 6
241000606125 Bacteroides Species 0.000 claims description 4
CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
241000193403 Clostridium Species 0.000 claims description 3
244000052616 bacterial pathogen Species 0.000 claims description 3
229960003866 cefaloridine Drugs 0.000 claims description 3
210000000936 intestine Anatomy 0.000 claims description 3
108010077805 Bacterial Proteins Proteins 0.000 claims description 2
238000010348 incorporation Methods 0.000 claims 1
108010042582 tosylarginine methyl ester hydrolase Proteins 0.000 claims 1
230000000968 intestinal effect Effects 0.000 abstract description 10
241001148471 unidentified anaerobic bacterium Species 0.000 abstract description 4
230000001717 pathogenic effect Effects 0.000 abstract description 3
229960004755 ceftriaxone Drugs 0.000 description 15
VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 15
241000700159 Rattus Species 0.000 description 12
241000606219 Bacteroides uniformis Species 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
210000003608 fece Anatomy 0.000 description 5
241000233866 Fungi Species 0.000 description 3
238000003556 assay Methods 0.000 description 3
-1 carboxyphenyl temocillin Chemical compound 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
230000002550 fecal effect Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
241000222122 Candida albicans Species 0.000 description 2
241000305071 Enterobacterales Species 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
230000003816 axenic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 description 1
WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000606124 Bacteroides fragilis Species 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
241000193171 Clostridium butyricum Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000605986 Fusobacterium nucleatum Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241001135219 Prevotella disiens Species 0.000 description 1
241001135261 Prevotella oralis Species 0.000 description 1
241000605860 Prevotella ruminicola Species 0.000 description 1
241001528479 Pseudoflavonifractor capillosus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000831652 Salinivibrio sharmensis Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
XMQVYNAURODYCQ-SLFBBCNNSA-N apalcillin Chemical compound C1([C@@H](NC(=O)C=2C(=C3N=CC=CC3=NC=2)O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 XMQVYNAURODYCQ-SLFBBCNNSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
229960003623 azlocillin Drugs 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
229960003644 aztreonam Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
229960003012 cefamandole Drugs 0.000 description 1
229960001139 cefazolin Drugs 0.000 description 1
MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
229960004682 cefoperazone Drugs 0.000 description 1
229960004261 cefotaxime Drugs 0.000 description 1
GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
229960001991 ceftizoxime Drugs 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960003326 cloxacillin Drugs 0.000 description 1
LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229920002457 flexible plastic Polymers 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000012212 insulator Substances 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
229960000198 mezlocillin Drugs 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229940041009 monobactams Drugs 0.000 description 1
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
229960001019 oxacillin Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
229960002292 piperacillin Drugs 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
229940046307 sodium thioglycolate Drugs 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229960001114 temocillin Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
229960004659 ticarcillin Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000020832 water fasting Nutrition 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PT87190A 1987-04-10 1988-04-08 Processo para a preparacao de composicoes farmaceuticas para a reducao dos efeitos indesejaveis das beta-lactaminas PT87190B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8705110A FR2613624B1 (fr)	1987-04-10	1987-04-10	Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines

Publications (2)

Publication Number	Publication Date
PT87190A PT87190A (pt)	1988-05-01
PT87190B true PT87190B (pt)	1992-08-31

Family

ID=9350003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT87190A PT87190B (pt)	1987-04-10	1988-04-08	Processo para a preparacao de composicoes farmaceuticas para a reducao dos efeitos indesejaveis das beta-lactaminas

Country Status (8)

Country	Link
EP (1)	EP0309532A1 (fr)
JP (1)	JPH01503537A (fr)
AU (1)	AU604117B2 (fr)
FR (1)	FR2613624B1 (fr)
OA (1)	OA09023A (fr)
PT (1)	PT87190B (fr)
WO (1)	WO1988007865A1 (fr)
ZA (1)	ZA882426B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI920206A0 (fi) *	1992-01-17	1992-01-17	Pekka Untamo Heino	Medicinsk anvaendning, medicinskt foerfarande och preparat.
FR2843302B1 (fr) *	2002-08-09	2004-10-22	Centre Nat Rech Scient	Forme galenique pour la delivrance colique de principes actifs
US8273376B2 (en)	2006-11-17	2012-09-25	Da Volterra	Colonic delivery of metallo-dependent enzymes
FI20105572A0 (fi)	2010-05-24	2010-05-24	Prevab R Lcc	Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
GB201117313D0 (en)	2011-10-07	2011-11-16	Gt Biolog Ltd	Bacterium for use in medicine
GB201306536D0 (en)	2013-04-10	2013-05-22	Gt Biolog Ltd	Polypeptide and immune modulation
BR112016023360B1 (pt)	2014-04-17	2023-03-07	Synthetic Biologics, Inc	Beta-lactamase e seu uso
JP6803328B2 (ja)	2014-08-28	2021-01-06	シンセティックバイオロジクス，インコーポレイテッド	大腸菌ベースでのベータラクタマーゼ生産
WO2016057744A1 (fr)	2014-10-08	2016-04-14	Synthetic Biologics, Inc.	Formulations de bêta-lactamase et utilisations de celles-ci
EP3236993B1 (fr)	2014-12-23	2023-09-13	Theriva Biologics, Inc.	Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux
EP3400953A1 (fr)	2014-12-23	2018-11-14	4D Pharma Research Limited	Polypeptide pirin et modulation immunitaire
AR103260A1 (es)	2014-12-23	2017-04-26	4D Pharma Res Ltd	Modulación inmunitaria
EP3261662B1 (fr)	2015-02-23	2021-07-21	Synthetic Biologics Inc.	Carbapénémases à utiliser avec des antibiotiques pour la protection du microbiome intestinal
EP3265119B1 (fr)	2015-03-06	2023-10-11	Theriva Biologics, Inc.	Dosage de beta-lactamase sûr et efficace pour la protection du microbiome
WO2016203221A1 (fr)	2015-06-15	2016-12-22	4D Pharma Research Limited	Compositions comprenant des souches bactériennes
NZ737752A (en)	2015-06-15	2022-02-25	4D Pharma Res Ltd	Compositions comprising bacterial strains
MA41010B1 (fr)	2015-06-15	2020-01-31	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
SMT201900588T1 (it)	2015-06-15	2019-11-13	4D Pharma Res Limited	Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41060B1 (fr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
CN108513545B (zh)	2015-11-20	2020-11-03	4D制药研究有限公司	包含细菌菌株的组合物
GB201520497D0 (en)	2015-11-20	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
ME03487B (fr)	2016-03-04	2020-01-20	4D Pharma Plc	Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
GB201612191D0 (en)	2016-07-13	2016-08-24	4D Pharma Plc	Compositions comprising bacterial strains
TWI802545B (zh)	2016-07-13	2023-05-21	英商４Ｄ製藥有限公司	包含細菌菌株之組合物
GB201621123D0 (en)	2016-12-12	2017-01-25	4D Pharma Plc	Compositions comprising bacterial strains
DK3630136T3 (da)	2017-05-22	2021-05-25	4D Pharma Res Ltd	Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (fr)	2017-05-24	2022-11-30	4D Pharma Research Limited	Compositions comprenant des souches bactériennes
CA3066189A1 (fr)	2017-06-14	2018-12-20	4D Pharma Research Limited	Compositions comprenant des souches bacteriennes
SMT202000555T1 (it)	2017-06-14	2020-11-10	4D Pharma Res Limited	Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it)	2017-06-14	2021-01-05	4D Pharma Res Limited	Composizioni comprendenti ceppi batterici

1987
- 1987-04-10 FR FR8705110A patent/FR2613624B1/fr not_active Expired - Lifetime
1988
- 1988-04-07 ZA ZA882426A patent/ZA882426B/xx unknown
- 1988-04-08 JP JP63503346A patent/JPH01503537A/ja active Pending
- 1988-04-08 WO PCT/FR1988/000172 patent/WO1988007865A1/fr not_active Ceased
- 1988-04-08 PT PT87190A patent/PT87190B/pt not_active IP Right Cessation
- 1988-04-08 AU AU15786/88A patent/AU604117B2/en not_active Ceased
- 1988-04-08 EP EP88903277A patent/EP0309532A1/fr not_active Withdrawn
- 1988-12-09 OA OA59487A patent/OA09023A/fr unknown

Also Published As

Publication number	Publication date
OA09023A (fr)	1991-03-31
PT87190A (pt)	1988-05-01
EP0309532A1 (fr)	1989-04-05
WO1988007865A1 (fr)	1988-10-20
FR2613624A1 (fr)	1988-10-14
ZA882426B (en)	1988-09-28
AU604117B2 (en)	1990-12-06
AU1578688A (en)	1988-11-04
FR2613624B1 (fr)	1990-11-23
JPH01503537A (ja)	1989-11-30

Legal Events

Date

Code

Title

Description

1992-08-31

FG3A

Patent granted, date of granting

Effective date: 19920204

1994-01-31

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19930831

Publication	Publication Date	Title
PT87190B (pt)	1992-08-31	Processo para a preparacao de composicoes farmaceuticas para a reducao dos efeitos indesejaveis das beta-lactaminas
Stevens et al.	1987	Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens
Weinstein et al.	1975	Antimicrobial therapy of experimental intraabdominal sepsis
US3320130A (en)	1967-05-16	Medicament for colitis, gastroenteritis and enterocolitis
KR0149672B1 (ko)	1998-10-15	클로스트리듐 디피실레 하리증 및 위막성 대장염의 예방 및 치료용 의약조성물
Onderdonk et al.	1979	Activity of metronidazole against Escherichia coli in experimental infra-abdominal sepsis
JP3140049B2 (ja)	2001-03-05	病原性腸内細菌をコントロールするための医薬製剤
EP0760848B1 (fr)	1998-02-04	Souches de lactobacillus d'origine humaine, leurs compositions et leurs utilisations
JP3186202B2 (ja)	2001-07-11	親生物
US6149908A (en)	2000-11-21	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
US8097247B2 (en)	2012-01-17	Probiotic, lactic acid-producing bacteria and uses thereof
US20040067223A1 (en)	2004-04-08	Probiotic compositions for the treatment of inflammatory bowel disease
FR2828M (fr)	1964-11-02	Médicament renfermant des colibacilles antibiorésistants.
Rimler	1979	Studies of the pathogenic avian haemophili
US4892731A (en)	1990-01-09	Biological intestinal antiseptics
JPH0656680A (ja)	1994-03-01	凍結乾燥された乳酸菌を含有する栄養学的及び／又は薬学的組成物、それらの調製及び使用
JP2012024092A (ja)	2012-02-09	Ｂａｃｉｌｌｕｓｃｏａｇｕｌａｎｓによる病原体の阻害
WO2021170137A1 (fr)	2021-09-02	Composition antitumorale
US5308615A (en)	1994-05-03	Probiotic for control of Salmonella
Burdon et al.	1979	Antibiotic susceptibility of Clostridium difficile
Brook et al.	1988	Effect of antimicrobial therapy on bowel flora and bacterial infection in irradiated mice
Gomez-Garces et al.	1995	Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents
RU2203946C1 (ru)	2003-05-10	Штамм бактерий lactobacillus acidophilus n.v. ep 317/402-x "баланс-наринэ", используемый для приготовления противогастритного и противоязвенного кисломолочного продукта
Buu-Hoi et al.	1988	Endocarditis caused by Capnocytophaga ochracea
US5455028A (en)	1995-10-03	Method of inhibiting fungi by Bacillus laterosporus